Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.
Am J Clin Oncol. 2010 Feb;33(1):96-100. doi: 10.1097/COC.0b013e3181817a75.
The realization that hyperthermia was an ideal complementary treatment to radiation and certain chemotherapeutic agents from a biologic perspective led to great enthusiasm for this modality over a quarter of a century ago. Unfortunately, this well-deserved enthusiasm quickly become tempered because of the inability to effectively heat tumors, particularly deep-seated ones with cumbersome first generation technology coupled with still-emerging understandings of thermal biology. Today as before, both challenges and opportunities remain in the application of hyperthermia for cancer patients. The lessons learned from the introduction of hyperthermia, a generation ago, are providing focus for application of this still-promising modality in today's clinic. These areas of challenge and opportunity include: thermal biology; treatment planning, delivery, and monitoring; successful high-quality clinical trials; and integration of thermal therapy with emerging technologies and therapeutic strategies both established and evolving. The progress made in understanding of thermal biology, physics, and bioengineering, coupled with advances in complementary clinical treatment modalities have all contributed to the next generation of clinical thermal therapy.
从生物学角度来看，人们认识到高热疗法是放疗和某些化疗药物的理想辅助治疗方法，这在四分之一个多世纪前引发了人们对该疗法的极大热情。不幸的是，由于无法有效地加热肿瘤，尤其是第一代技术复杂且对热生物学认识仍在不断发展的深部肿瘤，这种当之无愧的热情很快就消退了。时至今日，高热疗法在癌症患者中的应用仍然面临挑战和机遇。上一代引入高热疗法所积累的经验教训为当前临床应用这一仍有前途的治疗方法提供了重点。这些挑战和机遇领域包括：热生物学；治疗计划、实施和监测；高质量临床试验的成功开展；以及将热疗与新兴技术和治疗策略（已确立和正在发展的）相结合。对热生物学、物理学和生物工程的理解的进步，以及互补临床治疗方法的进步，都推动了下一代临床热疗的发展。
